6 results on '"D. Driscoll"'
Search Results
2. Identifying disparities in germline and somatic testing for ovarian cancer.
- Author
-
Huang M, Kamath P, Schlumbrecht M, Miao F, Driscoll D, Oldak S, Slomovitz B, Koru-Sengul T, and George S
- Subjects
- Adult, Aged, Aged, 80 and over, BRCA1 Protein genetics, BRCA2 Protein genetics, Female, Genetic Testing economics, Germ-Line Mutation, Humans, Medicaid economics, Medicaid statistics & numerical data, Medicare economics, Middle Aged, Mutation, Neoplasm Recurrence, Local genetics, Ovarian Neoplasms economics, Ovarian Neoplasms genetics, Retrospective Studies, United States, Young Adult, Genetic Testing statistics & numerical data, Healthcare Disparities statistics & numerical data, Neoplasm Recurrence, Local diagnosis, Ovarian Neoplasms diagnosis
- Abstract
Objective: Germline mutations occur in approximately 25% of patients with epithelial ovarian cancers while somatic BRCA mutations are estimated at 5-7%. The objectives of this study were to determine the rate of germline and somatic testing in women with ovarian cancer and to identify disparities in testing at a comprehensive cancer center (CCC) and a safety net hospital (SNH)., Methods: Patients treated for ovarian cancer from 2011 to 2016 were included. Clinicopathologic data were abstracted from the electronic medical records. Logistic regression modeling were performed to calculate odds ratios (OR) and corresponding 95% confidence intervals (95%CI)., Results: Out of 367 women, 55.3% completed germline testing; 27.0% received somatic testing. Women at the CCC were more likely to be tested for germline (60.4% vs 38.1%, p ≤ 0.001) and somatic (34.3% vs 2.4%, p ≤ 0.001) mutations than those at the SNH. Patients with Medicare (aOR = 0.51, 95%CI 0.28-0.94, p = 0.032) or Medicaid (aOR = 0.42, 95%CI 0.18-0.99, p = 0.048) were less likely to receive germline testing than those privately insured. Patients with Medicaid were less likely to receive somatic testing (aOR = 0.15, 95%CI 0.04-0.62, p = 0.009) than those privately insured. Women with disease recurrence had a higher likelihood of being tested for germline (OR = 3.64, 95%CI 1.94-6.83, P < 0.001) and somatic (OR = 7.89, 95%CI 3.41-18.23, p < 0.001) mutations. There was no difference in germline or somatic testing by race/ethnicity., Conclusions: Disparities in both germline and somatic testing exist. Understanding and overcoming barriers to testing may improve cancer-related mortality by allowing for more tailored treatments as well as for improved cascade testing., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
3. Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer.
- Author
-
Sharma S, Rezai K, Driscoll D, Odunsi K, and Lele S
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carboplatin administration & dosage, Carboplatin adverse effects, Chemotherapy, Adjuvant, Enterobacteriaceae Infections complications, Enterobacteriaceae Infections etiology, Enterococcus isolation & purification, Escherichia coli isolation & purification, Escherichia coli Infections chemically induced, Escherichia coli Infections etiology, Female, Humans, Klebsiella isolation & purification, Middle Aged, Neutropenia chemically induced, Neutropenia microbiology, Ovarian Neoplasms drug therapy, Ovarian Neoplasms surgery, Paclitaxel administration & dosage, Paclitaxel adverse effects, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols adverse effects, Fever etiology, Neutropenia complications, Ovarian Neoplasms complications
- Abstract
Objectives: Limited information is available on the incidence and characteristics of neutropenic fever (NF) in patients receiving contemporary regimens for epithelial ovarian cancer (EOC). We examined this issue in patients receiving first-line adjuvant chemotherapy with platinum- and paclitaxel-based regimens at a major cancer institute., Methods: Charts of patients with EOC at a single institute from 1998 through 2002 were reviewed. Data were collected on the incidence and duration of NF, duration of hospitalization and fever, cultures, antibiotic and chemotherapy regimen, and type of debulking procedure., Results: 140 patients were treated for EOC. 125 patients received first line chemotherapy. 15 episodes of NF were observed. Mean duration of neutropenia and fever was 2.33 and 3.07 days respectively. 9 of 15 (60%) NF episodes occurred after cycle 1. Cultures were positive in 7 of 15 patients (47%). Organisms most frequently recovered were bowel-derived. 8 patients (53%) had bowel resections, and 15 patients (100%) had radical or supraradical procedures. There was a correlation between incidence of NF and type of procedure (P = 0.01) and stage of EOC (P = 0.04). There was no correlation between NF and elderly age, medical comorbidities, and postoperative complications., Conclusions: The rate of NF was higher than previously reported. NF occurred most frequently after cycle 1. NF patients were of advanced stage that had undergone more aggressive surgery and had bowel resections. Our data suggest that patients with advanced EOC who undergo more radical procedures should be identified as high risk for developing NF in early cycles.
- Published
- 2006
- Full Text
- View/download PDF
4. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer.
- Author
-
Hylander B, Repasky E, Shrikant P, Intengan M, Beck A, Driscoll D, Singhal P, Lele S, and Odunsi K
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Gene Expression, Genes, Wilms Tumor, Humans, Immunohistochemistry, Middle Aged, Neoplasm Staging, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology, Ovarian Neoplasms therapy, Peritoneal Neoplasms genetics, Peritoneal Neoplasms metabolism, Peritoneal Neoplasms pathology, Peritoneal Neoplasms therapy, Treatment Outcome, WT1 Proteins genetics, Ovarian Neoplasms metabolism, WT1 Proteins biosynthesis
- Abstract
Objectives: The identification of proteins that are selectively expressed in cancer and with potential to elicit an immune response is the first step towards antigen-specific immunotherapy. The Wilms tumor gene product (WT1) is inherently immunogenic and is now thought to be oncogenic. The aim of this study was to determine the expression of WT1 in epithelial ovarian cancer (EOC) and correlate with clinico-pathologic characteristics., Methods: WT1 expression was examined using immunohistochemistry applied on a tissue microarray of normal tissues and a panel of 100 EOC tissues. The distribution of WT1 expression and clinico-pathologic variables were analyzed. Survival probabilities were estimated by Kaplan-Meier method, and statistical significance was determined by the log-rank test., Results: WT1 expression was observed in 78/100 of specimens. The predominant expression pattern was homogenous, occurring in 66/100 (66%) of WT1-positive specimens, while 12/100 (12%) demonstrated heterogeneous staining. In normal tissues, WT1 expression was noted in kidneys, splenic capsule, Sertoli cells of the testis, and granulosa cells of the ovary. The median follow-up of the patient population was 30 months. Patients with WT1-positive tumors tended to have a higher grade (P = 0.006) and stage (P = 0.002) of tumor. However, there were no significant differences in the distribution of patients with WT1-positive tumors in relation to disease-free and overall survival., Conclusions: Our data demonstrate that WT1 is expressed at high frequency in patients with EOC. Since WT1 demonstrates tissue-restricted expression and is inherently immunogenic, it could represent an attractive target for antigen-specific immunotherapy in EOC.
- Published
- 2006
- Full Text
- View/download PDF
5. A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer.
- Author
-
Sharma S, Qian F, Keitz B, Driscoll D, Scanlan MJ, Skipper J, Rodabaugh K, Lele S, Old LJ, and Odunsi K
- Subjects
- A Kinase Anchor Proteins, Adaptor Proteins, Signal Transducing biosynthesis, Adult, Aged, Aged, 80 and over, Epithelial Cells pathology, Female, Humans, Middle Aged, Neoplasm Staging, Ovarian Neoplasms metabolism, Ovarian Neoplasms pathology, RNA, Messenger genetics, Survival Rate, Adaptor Proteins, Signal Transducing genetics, Ovarian Neoplasms genetics, RNA, Messenger biosynthesis
- Abstract
Objectives: Cancer-testis (CT) antigens are expressed in tumors but not normal tissues except the testis and could be targets for vaccine therapy in epithelial ovarian cancer (EOC). A-kinase anchoring protein 3 (AKAP-3) is a novel member of the CT antigen family. The aim of this study was to examine the expression of AKAP-3 in EOC and correlate with clinico-pathologic characteristics., Methods: One step RT-PCR was performed with RNA from normal and ovarian cancer cell lines and 74 epithelial ovarian tumor tissues. AKAP-3-specific PCR product was amplified. The distribution of AKAP-3 expression and clinico-pathologic variables was analyzed. Survival distributions were estimated, and multivariate analyses were performed., Results: AKAP-3 mRNA expression was demonstrated in 43/74 (58%) of the ovarian cancer specimens. AKAP-3 was expressed in normal testis, but not in other normal tissues. AKAP-3 expression significantly correlated with increased likelihood of residual tumor (P = 0.005), but no increase in the likelihood of recurrence or persistent disease (P = 0.06). Patients with AKAP-3 mRNA expression were found to have a significantly poorer overall survival (median 50 months) compared with patients without AKAP-3 expression (median not reached) (P = 0.007). Multivariate analysis of AKAP-3 expression, residual disease, and response to frontline chemotherapy found response to be the strongest predictor of overall survival (P = 0.012)., Conclusions: Our data demonstrate that AKAP-3 is expressed at high frequency in patients with EOC. Since AKAP-3 demonstrates tumor-restricted expression and appears to be associated with worse overall survival, it could represent an attractive target for antigen-specific immunotherapy in EOC.
- Published
- 2005
- Full Text
- View/download PDF
6. Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases.
- Author
-
Anupol N, Ghamande S, Odunsi K, Driscoll D, and Lele S
- Subjects
- Adult, Aged, Combined Modality Therapy, Female, Humans, Middle Aged, Prognosis, Regression Analysis, Retrospective Studies, Survival Analysis, Treatment Outcome, Brain Neoplasms secondary, Brain Neoplasms therapy, Ovarian Neoplasms pathology, Ovarian Neoplasms therapy
- Abstract
Objective: The objective of this study is to evaluate the impact of different clinical variables and treatment modalities on survival in patients with brain metastases from ovarian carcinoma., Methods: Methods included: (1) retrospective chart review of all patients with ovarian cancer and brain metastases from 1986 to 2000 at Roswell Park Cancer Institute and (2) Medline search was performed to extract data from all published reports with three or more cases of ovarian cancer with brain metastases. Cox regression analysis, Kaplan-Meier test, and log rank test were used to calculate survival and compare the impacts of clinical variables and treatment modalities., Results: Fifteen patients with brain metastases out of 1042 women with ovarian carcinoma were identified from our institution, an incidence of 1.4%. The median time from initial diagnosis to detection of brain metastases was 22 months. Patients who were not treated after brain metastasis had a median survival of 0.5 month versus 6 months with therapy. In the subgroup of patients treated with a combination of radiation, surgery, and chemotherapy, the median survival was 22 months. Literature analysis combined with our data generated 124 patients. The only clinically significant variable impacting survival was the presence or absence of additional distant recurrence with median survivals of 3 and 8 months, respectively (P = 0.005). Among patients who received treatment, the combination of radiation and surgery with or without chemotherapy appears to be beneficial, with a median survival of 20 months (P < 0.001)., Conclusion: Patients with brain metastases from ovarian cancer without any evidence of disease in other sites appear to benefit from aggressive combined treatment with external radiation and surgery with or without chemotherapy with a median survival of 20 months.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.